• ACS patients at high risk for ischemic events after successful PCI with implantation of at least one drug eluting stent

• Able and willing to provide informed consent and participate in 12 months follow-up period

• Able to receive DAPT treatment

• Enrollment into the study will require meeting at least one angiographic or clinical inclusion and none of the exclusion criteria.

∙ Clinical inclusion criteria:

⁃ Family history of premature coronary heart disease (Coronary heart disease in first-degree male relative \<55 years old or in first-degree female relative \<65 years old)

⁃ Repeated myocardial infarction

⁃ Positive serum cardiac troponin I/T

⁃ Combined with at least one organ/system with atherosclerotic disease (e.g. intracranial or peripheral arteries)

⁃ Type 2 diabetes mellitus under medication

⁃ Chronic kidney disease (eGFR\<60 mL/min/1.73 m2 or CrCl\<60ml/min)

∙ Angiographic Inclusion Criteria:

⁃ LM lesion requiring stents

⁃ Proximal LAD lesion(s) requiring stents

⁃ Bypass grafts lesion(s) requiring stents

⁃ Overall stent length ≥60 mm

⁃ History of in-stent thrombosis

⁃ Bifurcation lesions requiring at least 2 stents

⁃ Over two vessels lesions requiring stents

⁃ Calcified target lesion(s) requiring atherectomy

⁃ The intraoperative occurrence of no-reflow or slow-flow

‣ Compressed branch vessels with a diameter of at least 2.0 mm failing to reach flow restoration (at least TIMI 3)